|
Take Solutions held its Analyst Meet on 31 October 2018 to discuss results.
H R Srinivasan Vice Chairman & M.D of the company addressed the meet.
Highlights of the call:
Take Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management. In the fast-growing Life Sciences space, it offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise.
It recorded a high growth rate this quarter.
Revenue at Rs 515.87 crore grew 39.08% Y-o-Y and 10.34% Q-o-Q
PAT at Rs 60.79 crore, grew 65.68% Y-o-Y.
Six month revenue stood at Rs 1005.05 crore against Rs 727.47 crore.
Six months net profit grew 59%, to Rs 114.96 crore.
For the quarter sales grew partly due to depreciation in the value of the rupee.
In dollar terms, the sequential growth was nearly half of that at 5.54% to $ 73.58 mln. EBITDA grew 8.13% to $ 15.03 million.
H1 tax rate grew from 13.44% to 16.21%.
The company continues to invest ahead of the growth curve in the right technology and infrastructure to position itself as the most preferred partner for global pharmas.
The company has clients from across the globe, including biopharmaceutical companies and generics manufacturers.
During the quarter it successfully exited US Supply Chain Business.
It has operations spread across North America, Europe, Asia, and South America.
The company is seeing increased t raction in Consulting Business both in terms of volume and size.
Gartner recognized TAKE Solutions amongst Top 20 Global Solution Providers in its Market Guide for Track-and-Trace and Serialization Software Providers for Life Sciences Companies Regulatory, clinical trials, Research & Development Awards and recognition.
It received multi-year, multi-million dollar engagement with top global pharma company for Clinical Services.
It is on track of 2021 internal growth strategy.
It has strong order book of $227.57, which saw a growth of 13.9% QoQ.
The company is seeing a consistent growth trajectory.
It has a healthy cash balance and a strong pipeline of key prospects to complete its expansion in key markets including North America and Europe.
It has also received multiple transformative deals in regulatory and pharmaco-vigilance.
|